Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis
Table 1
Patient baseline demographic and clinical characteristics (unmatched).
Characteristics
cTACE ()
cTACE+HAIC ()
value
Standardized mean difference
Age (years)†
0.680
0.058
Sex
0.963
0.008
Male
60 (87.0)
75 (87.2)
Female
9 (13.0)
11 (12.8)
Etiology
0.883
0.020
Hepatitis B virus
60 (87.0)
73 (84.9)
Hepatitis C virus
3 (4.3)
6 (7.0)
Unknown/other
6 (8.7)
7 (8.1)
Cirrhosis clinical course
0.496
Stage 1-2
59 (85.5)
70 (81.4)
Stage 3-4
10 (14.5)
16 (18.6)
Child-Pugh class
0.316
0.184
A
62 (89.9)
81 (94.2)
B
7 (10.1)
5 (5.8)
ALB grade
0.417
0
65 (94.2)
78 (90.7)
1-2
4 (5.8)
8 (9.3)
ECOG performance status
0.336
0.153
0
43 (62.3)
47 (54.7)
1-2
26 (37.7)
39 (45.3)
Portal vein invasion stage
0.019
0.173
Vp1-2
12 (17.4)
4 (4.7)
Vp3
30 (43.5)
51 (59.3)
Vp4
27 (39.1)
31 (36.0)
Extrahepatic spread
0.952
0.010
Absent
43 (62.3)
54 (62.8)
Present
26 (37.7)
32 (37.2)
Tumor diameter (mm)
0.520
0.104
>100
30 (43.5)
34 (39.5)
≤100
39 (56.5)
52 (60.5)
(mm)†
0.622
AFP (ng/mL)‡
2429.50 ()
3919.00 ()
0.454
0.066
≤1000
29 (42.0)
39 (45.3)
0.679
>1000
40 (58.0)
47 (54.7)
ALB: albumin; TACE: transcatheter arterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy; AFP: serum α-fetoprotein level; SD: standard deviation. †Data .‡Data were median (full range). Unless indicated otherwise, data are the number of patients, with percentages in parentheses. Continuous variables were analyzed using the two-sample test, or the Wilcoxon rank-sum test was used. Categorical variables were compared by using the test.
